SearchDictionaryMobileLogin

Gerald I Shulman Selected Research

Insulin Resistance

10/2007Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance.
08/2007Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
03/2007Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.
03/2006Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.
07/2005Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart.
07/2005Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice.
06/2005Adipocyte-specific overexpression of FOXC2 prevents diet-induced increases in intramuscular fatty acyl CoA and insulin resistance.
06/2004Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action.
03/2004Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle.
03/2004Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance.
09/2003Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning.
08/2003Insulin resistance in tetracycline-repressible Munc18c transgenic mice.
06/2003Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
05/2002Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Articles by Research Topic

Disease

14Insulin Resistance
10/2007 - 05/2002
2Syndrome
08/2007 - 09/2003
2Hypoglycemia (Reactive Hypoglycemia)
05/2007 - 10/2005
2Obesity
07/2006 - 03/2004
2Stroke (Strokes)
01/2005 - 06/2003
2Transient Ischemic Attack
01/2005 - 06/2003
1Body Weight (Weight, Body)
05/2008
1Hypersensitivity (Allergy)
03/2007
1Fatty Liver
03/2007
1Glucose Intolerance
09/2006
1Infertility (Sterility)
03/2004
1Prediabetic State (Prediabetes)
09/2003
1Weight Loss (Weight Reduction)
10/2002
1Lipodystrophy
05/2002
1Hyperinsulinism (Hyperinsulinemia)
02/2002
1Hyperglycemia
02/2002

Drug/Important Bio-Agent (IBA)

5Insulin (Novolin)FDA Link
03/2007 - 10/2002
4Glucose (Dextrose)FDA LinkGeneric
08/2007 - 02/2002
2Phosphotransferases (Kinase)IBA
03/2007 - 07/2006
2Acyl Coenzyme A (Acyl CoA)IBA
07/2005 - 06/2005
1TransferasesIBA
05/2008
1Carnitine (L-Carnitine)FDA LinkGeneric
05/2008
1Long-Chain Acyl-CoA Dehydrogenase (Long-Chain-Acyl-Coenzyme A Dehydrogenase)IBA
10/2007
1Antisense OligonucleotidesIBA
08/2007
1protein kinase C lambdaIBA
08/2007
1Glutamic Acid (Glutamate)FDA Link
05/2007
1Protein Kinases (Protein Kinase)IBA
03/2007
1CD66 antigensIBA
09/2006
1Acetyl Coenzyme A (Acetyl-CoA)IBA
03/2006
1LipidsIBA
10/2005
1Sterol Esterase (Hormone-Sensitive Lipase)IBA
07/2005
1Glycerol (Glycerine)FDA LinkGeneric
07/2005
1AntigensIBA
06/2004
1Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA
06/2004
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
03/2004
1Fatty Acid Transport Proteins (Fatty Acid Transport Protein)IBA
03/2004
1malonyl-CoA decarboxylaseIBA
03/2004
1Tetracycline (Achromycin)FDA LinkGeneric
08/2003
1rosiglitazone (Avandia)FDA Link
06/2003
1pioglitazone (Actos)FDA Link
06/2003
1LeptinIBA
05/2002
1FructoseIBA
02/2002